Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up [Yahoo! Finance]
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an "outperform" rating on the stock.
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript [Yahoo! Finance]